Freestone Capital Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Freestone Capital Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$499K	Buy	1,004 +104	+12%	+$46.1K	0.01%	385
2026 Q1	$402K	Buy	900 +51	+6%	+$23.8K	0.01%	375
2025 Q4	$385K	Sell	849 -63	-7%	-$27.2K	0.01%	385
2025 Q3	$357K	Buy	+912	New	+$381K	0.01%	402
2022 Q3	–	Sell	-1,016	Closed	-$286K	–	440
2022 Q2	$286K	Sell	1,016 -397	-28%	-$106K	0.01%	342
2022 Q1	$369K	Sell	1,413 -43	-3%	-$10.2K	0.01%	426
2021 Q4	$320K	Buy	+1,456	New	+$283K	0.01%	390
2021 Q3	–	Sell	-1,244	Closed	-$251K	–	442
2021 Q2	$251K	Sell	1,244 -38	-3%	-$7.95K	0.01%	367
2021 Q1	$275K	Buy	1,282 +326	+34%	+$71.6K	0.02%	343
2020 Q4	$226K	Buy	956 +234	+32%	+$53.7K	0.01%	333
2020 Q3	$196K	Buy	+722	New	+$199K	0.01%	321

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Freestone Capital Holdings's VRTX Position: Q2 2026 in Review

Freestone Capital Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $46.1K and bringing the position to 1,004 shares worth $499K. The position accounts for 0.01% of the portfolio, ranked #385.

Freestone Capital Holdings first reported a position in VRTX in Q3 2020 and has held it in 11 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Freestone Capital Holdings held 1,004 shares of Vertex Pharmaceuticals worth $499K as of Q2 2026.
Freestone Capital Holdings bought 104 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.1K.
Vertex Pharmaceuticals made up 0.01% of Freestone Capital Holdings's portfolio in Q2 2026, its #385 holding.
Freestone Capital Holdings first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.